Lloyds Pharmacy

Sheffield, United Kingdom

Lloyds Pharmacy

Sheffield, United Kingdom

Time filter

Source Type

Receive press releases from iHealthcareAnalyst, Inc.: By Email Global Online Pharmacies Market Analysis: Geography, Growth Trends and Forecast to 2020, New Findings by iHealthcareAnalyst, Inc. Online Pharmacies Market by Geography – North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World 2016-2020. Maryland Heights, MO, February 25, 2017 --( Browse Online Pharmacies Market by Geography – North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World 2016-2020 at https://www.ihealthcareanalyst.com/report/online-pharmacies-market/. An online pharmacy, Internet pharmacy, e-pharmacy or mail-order pharmacy is a pharmacy that operate over the Internet and sends the orders to customers through the mail or shipping companies. Most attractive feature of online pharmacies is drug prices. Customers can sometimes obtain 50 to 80 percent or more savings on U.S. drugs and medicines prices at foreign pharmacies. Independent research published by the National Bureau of Economic Research demonstrates that online pharmacies, U.S. and foreign, verified by certain credentialing entities, sell genuine medication and require a prescription. It further states that, all tested prescription drug orders were found to be authentic when ordered from online pharmacies, international and U.S.-only, approved by PharmacyChecker.com, as well as U.S. online pharmacies approved by the National Association of Boards of Pharmacy (NABP), Verified Internet Pharmacy Practice Sites (VIPPS) program or LegitScript, whereas 90 percent of tested products ordered from non-credentialed online pharmacies were counterfeit. The global online pharmacies market is segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. The global online pharmacies market report provides market size (Revenue USD Million 2013 to 2020), market share and forecasts growth trends (CAGR%, 2016 to 2020). The global online pharmacies market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. The global online pharmacies market report also provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments. Major players operating in the global online pharmacies market and profiled in this report include Banner Health, CVS Caremark, DocMorris NV, Dr. Fox Pharmacy, eDrugstore.MD, Lloyds Pharmacy Ltd., MediSave, PlanetRX.com Inc., Rowlands Pharmacy, and Walgreen Co. To request Table of Contents and Sample Pages of this report visit: https://www.ihealthcareanalyst.com/report/online-pharmacies-market/ About Us iHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals. In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study. Contact Us iHealthcareAnalyst, Inc. 2109, Mckelvey Hill Drive Maryland Heights, MO 63043 United States Email: sales@ihealthcareanalyst.com Website: https://www.ihealthcareanalyst.com Maryland Heights, MO, February 25, 2017 --( PR.com )-- The global online pharmacies market is estimated to reach USD 65.5 Billion by 2020, growing at a CAGR of 17.4% from 2016 to 2020.Browse Online Pharmacies Market by Geography – North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World 2016-2020 at https://www.ihealthcareanalyst.com/report/online-pharmacies-market/.An online pharmacy, Internet pharmacy, e-pharmacy or mail-order pharmacy is a pharmacy that operate over the Internet and sends the orders to customers through the mail or shipping companies. Most attractive feature of online pharmacies is drug prices. Customers can sometimes obtain 50 to 80 percent or more savings on U.S. drugs and medicines prices at foreign pharmacies. Independent research published by the National Bureau of Economic Research demonstrates that online pharmacies, U.S. and foreign, verified by certain credentialing entities, sell genuine medication and require a prescription. It further states that, all tested prescription drug orders were found to be authentic when ordered from online pharmacies, international and U.S.-only, approved by PharmacyChecker.com, as well as U.S. online pharmacies approved by the National Association of Boards of Pharmacy (NABP), Verified Internet Pharmacy Practice Sites (VIPPS) program or LegitScript, whereas 90 percent of tested products ordered from non-credentialed online pharmacies were counterfeit.The global online pharmacies market is segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.The global online pharmacies market report provides market size (Revenue USD Million 2013 to 2020), market share and forecasts growth trends (CAGR%, 2016 to 2020). The global online pharmacies market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. The global online pharmacies market report also provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments.Major players operating in the global online pharmacies market and profiled in this report include Banner Health, CVS Caremark, DocMorris NV, Dr. Fox Pharmacy, eDrugstore.MD, Lloyds Pharmacy Ltd., MediSave, PlanetRX.com Inc., Rowlands Pharmacy, and Walgreen Co.To request Table of Contents and Sample Pages of this report visit: https://www.ihealthcareanalyst.com/report/online-pharmacies-market/About UsiHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study.Contact UsiHealthcareAnalyst, Inc.2109, Mckelvey Hill DriveMaryland Heights, MO 63043United StatesEmail: sales@ihealthcareanalyst.comWebsite: https://www.ihealthcareanalyst.com Click here to view the list of recent Press Releases from iHealthcareAnalyst, Inc.


UK. 23 January 2017. MML today announced a three-year extension to its maintenance management contract for the John Lewis Partnership. MML, a leading UK and European facilities management company, will continue to deliver an around-the-clock maintenance management service for the John Lewis Partnership retail and head office properties across the UK. MML provides a full managing agent service for the John Lewis Partnership offering 24/7 helpdesk support, facilities and asset management, statutory compliance, financial control and reporting. Marc Pinder, Operations Director UK at MML, said: “Our long-term relationship with the John Lewis Partnership is built on our ability to take care of all its facility management needs efficiently and transparently. Our continued collaboration is testament to the dedication of our valued staff and senior management.” About MML MML is a leading UK and European facilities management company working in partnership with its customers to offer impartial advice and a 24/7 fully managed maintenance service. With a reputation for working with recognised high street brands, such as the John Lewis Partnership and Lloyds Pharmacy, MML provides a full management agent service including 24/7 helpdesk support, facilities and asset management, statutory compliance, financial control and reporting. The Milton Keynes-based company employs 125 people and is a member of the BIFM, the professional body for Facilities Management. For further information visit: www.maintenance-management.com


Dudka J.,Medical University of Lublin | Korga A.,Medical University of Lublin | Gieroba R.,Medical University of Lublin | Walczyna B.,Medical University of Lublin | And 3 more authors.
Annales Universitatis Mariae Curie-Sklodowska, Sectio DDD: Pharmacia | Year: 2011

The most evidence suggests that the major cause of doxorubicin (DOX) cardiotoxicity is reactive oxygen species and consequently oxidative stress. The accumulation of oxidative damages leading to mitochondrial dysfunction results in contractility disorders. In a cell adaptive process against oxidative stress, the transcription factor Nrf2 (Nfe2) plays a crucial role by stimulating expression of genes controlling synthesis of enzymes taking part in oxidative defence and red-ox equilibrium, e.g. glucose-6-phosphate dehydrogenase, phosphogluconate dehydrogenase and malic enzyme. Expression of genes responsible for the synthesis of these enzymes is controlled by iodothyronine hormones. These facts lead to an assumption that the impact of anthracyclines on oxidative stress may differ in hyperthyroid and euthyroid individuals. In these studies first of all we tested the hypothesis that symptoms of oxidative stress may be evident long time since last dose of DOX and if hypothyreosis may change myocardium antioxidative response in rats which received DOX. There was no statistical difference in Nfe2 expression in hearts of rats after doxorubicin administrations (group of DOX) versus controls. In this group there were no statistical differences in cardiac NADPH and total mitochondrial glutathione concentrations and GSH/GSSG ratio comparing to the controls. Moreover, any changes in all tested parameters were observed between DOX vs. DOX+4T4. We concluded that after three weeks since last doxorubicin administration there were no significant signs of oxidative stress in the heart, and that in our study conditions there was no interaction of DOX and thyroxin referring to oxidative stress in the myocardium. Copyright © 2011 Medical University in Lublin.


Dudka J.,District Specialist Hospital of Stefan Cardinal Wyszynski in Lublin | Iwan M.,District Specialist Hospital of Stefan Cardinal Wyszynski in Lublin | Walczyna B.,District Specialist Hospital of Stefan Cardinal Wyszynski in Lublin | Wronecki L.,District Specialist Hospital of Stefan Cardinal Wyszynski in Lublin | And 3 more authors.
Annales Universitatis Mariae Curie-Sklodowska, Sectio DDD: Pharmacia | Year: 2010

Some cancer cells are typically characterized by hypoxia which is more resistant to radiotherapy and most common anticancer drugs. These specific phenomena encouraged researchers to the investigate new hypoxic-cell-selective cytotoxins. Tirapazamine (TPZ) is a representative of the drug-candidates group which demonstrates a considerable higher cytotoxic effect against hypoxic and then normoxic tumor cells studied under the same conditions. Taking into account that solid tumor does not only consist of hypoxic but also normoxic cells, a rational therapy should combine administration of classical anticancer therapy and TPZ. Results of some studies conducted under laboratory conditions indicated some benefits of such a schedule. Because doxorubicin (DOX), a widely used chemotherapeutic drug, has a similar mechanism of action as TPZ, we tested the hypothesis assuming interaction of both compounds in rats referring to blood toxicity. In this study we evaluated peripheral blood automatic smear in rats repeatedly treated with both DOX and TPZ. The major findings are that TPZ may statistically significantly change the relative amount of lymphocytes, MPV MCV and RDW in rats treated with DOX. Collectively, these findings suggest interactions between TPZ and DOX in relation to some red cells, white cells and platelets parameters, but the clinical risk of this phenomenon seems to be acceptable during chemotherapy. However, future studies are needed to assess the importance of anisocytosis as a result DOX-TPZ interaction.


Matysiak W.,Medical University of Lublin | Dudka J.,Medical University of Lublin | Korga A.,Medical University of Lublin | Zieba J.,Medical University of Lublin | And 4 more authors.
Annales Universitatis Mariae Curie-Sklodowska, Sectio DDD: Pharmacia | Year: 2010

Tirazapamine is a drug that has been shown to be a selective anticancer compound which was proved, in the latest studies, more efficient in concomitant treatment with other chemotherapeutic agents. In previous studies evidence suggested that the predominant mechanism DOX and TPZ cell toxicity is linked with the generation of reactive oxygen species. Moreover, under normal cell condition, CP decreased the level of reduced glutathione changing red-ox status. Then Redox equilibrium differences may have an impact on lipids, hydrocarbons and proteins metabolic transformations. In our study we tested the effect of TPZ in combination with DOX, CP and 5-FU on myocytes oxidative stress, triglycerides, glucose and proteins levels. The rats were treated (i.p.) with two doses (5 i 10 mg/kg b.w.) of tirapazamine, 2h before administration of 1.8 mg/kg b.w. of doxorubicin, 2 mg/kg b.w of cisplatin or 10 mg/kg b.w. of 5-fluorouracil. All tested drugs were administered once a week over a period of 6 weeks and a week after the last dose was given, and the obtained skeletal muscle samples were taken to be tasted. The data presented in this study support the assumption that TPZ changed the red-ox equilibrium in skeletal muscle of rats treated at the same time with DOX or FU. TPZ also caused metabolic disorders in rats treated simultaneously with CP. On the other hand, the lack of relationship between oxidative stress and metabolic disorders in the tested pairs of drugs suggested that these phenomena are independent under experimental conditions.


Sliwinska J.,Medical University of Lublin | Dudka J.,Medical University of Lublin | Korga A.,Medical University of Lublin | Burdan F.,Medical University of Lublin | And 4 more authors.
Oxidative Medicine and Cellular Longevity | Year: 2012

Doxorubicin (DOX) causes long-term cardiomyopathy that is dependent on oxidative stress and contractility disorders. Tirapazamine (TP), an experimental adjuvant drug, passes the same red-ox transformation as DOX. The aim of the study was to evaluate an effect of tirapazamine on oxidative stress, contractile protein level, and cardiomyocyte necrosis in rats administered doxorubicin. Rats were intraperitoneally injected six times once a week with tirapazamine in two doses, 5 (5TP) and 10mg/kg (10TP), while doxorubicin was administered in dose 1.8mg/kg (DOX). Subsequent two groups received both drugs simultaneously (5TP+DOX and 10TP+DOX). Tirapazamine reduced heart lipid peroxidation and normalised RyR2 protein level altered by doxorubicin. There were no significant changes in GSH/GSSG ratio, total glutathione, cTnI, AST, and SERCA2 level between DOX and TP+DOX groups. Cardiomyocyte necrosis was observed in groups 10TP and 10TP+DOX. © 2012 Justyna Sliwinska et al.


Korga A.,Medical University of Lublin | Dudka J.,Medical University of Lublin | Burdan F.,Medical University of Lublin | Sliwinska J.,Medical University of Lublin | And 2 more authors.
Oxidative Medicine and Cellular Longevity | Year: 2012

Oxidative stress and disorders in calcium balance play a crucial role in the doxorubicin-induced cardiotoxicity. Moreover, many cardiotoxic targets of doxorubicin are regulated by iodothyronine hormones. The aim of the study was to evaluate effects of tetraiodothyronine (0.2, 2mg/L) on oxidative stress in the cardiac muscle as well as contractility and cardiomyocyte damage markers in rats receiving doxorubicin (1.5mg/kg) once a week for ten weeks. Doxorubicin was administered alone (DOX) or together with a lower (0.2T 4 + DOX) and higher dose of tetraiodothyronine (2T 4 + DOX). Two groups received only tetraiodothyronine (0.2T 4, 2T 4). Coadministration of tetraiodothyronine and doxorubicin increased the level of lipid peroxidation products and reduced RyR2 level when compared to untreated control and group exposed exclusively to doxorubicin. Insignificant differences in SERCA2 and occasional histological changes were observed. In conclusion, an increase of tetraiodothyronine level may be an additional risk factor of redox imbalance and RyR2 reduction in anthracycline cardiotoxicity. Copyright 2012 Agnieszka Korga et al.


News Article | November 15, 2016
Site: techcrunch.com

A UK startup is angling to build a business out of simplifying the repeat prescription ordering process for NHS GP surgeries via an app, called Echo, that lets patients use their smartphones to make a request for more of their usual medication from their doctor. The app works by sending a user’s request to their GP, with approved prescriptions dispensed by Echo’s partner pharmacies after they receive a GP’s instruction — with the user granting Echo the authority to nominate a pharmacy partner to fulfill their electronic prescription requests on their behalf. Prescriptions are dispatched to users for free by the pharmacy via Royal Mail (second class post) meaning, from a user point of view, there’s no need to go to the GP or the pharmacy to obtain a repeat prescription. They just make an order via the app, pay for the prescription (unless they qualify for free NHS prescriptions) and wait to get their medication delivered. “Echo works with all NHS GP services in England,” says Stephen Bourke, CXO and co-founder. “We use existing prescription order workflows, leveraging a platform called NHS Electronic Prescription Service 2 (EPS2), so there is no change to the way they do things. For GPs not yet set-up on EPS2 (14% of practices in England), we work with existing systems. “Requests are sent a number of ways — via the GP practice’s workflow software, which integrates with our pharmacy side software, via secure email (from an internal NHS.NET account over N3) or via eFax.” While the NHS’s own electronic prescription service is aimed at simplifying repeat prescription ordering for patients, Bourke claims the service remains “fragmented” — and argues Echo offers a more streamlined approach, with less need for manual follow-up for patients once an order has been placed. “The current EPS service is fragmented and does not enable three-way communication between doctor, patient and pharmacist,” he argues. “An order placed via a Patient Facing Systems (which tend to be clunky and hard to use) places the request with the GP but does not involve the pharmacy. Inevitably the patient needs to follow up the order, either with the surgery or by going to the pharmacy. Echo manages each and every step of the way — the user places the order, we deliver the medication.” The app also uses natural language processing to convert GP directions into reminders — allowing Echo to automatically prompt users when to take their medication, as well as reminding them when they’re about to run out. So there’s an additional potential benefit for users worried about forgetting to take their medication at the right time. Asked how it’s handling sensitive user medical data, Bourke says: “We store data directly supplied by user — demographic, medication etc. — this is fully encrypted (SSL), stored on GCP/AWS and managed in accordance with [NHS information governance] Caldicott principles.” “Echo has a full time NHS doctor as well as a prescribing pharmacist on staff, who ensure information governance is kept front and centre,” he adds. While the business was founded back in July 2015, the Echo app is officially launching today — currently iOS only. The service has been tested prior to this official launch, with the team seeding it to friends and family, which they say resulted in it spreading “like wildfire”. At this point they have around 1,500 users, and 10 pharmacies across London and the South East able to dispatch prescriptions to anywhere in the UK. Also today they’re announcing a £1.8 million (~$2.2M) seed funding round led by LocalGlobe, with Global Founders Capital also participating. The team had previously raised £400k from angel investors to get to proof of concept. Bourke says the new funding will be used for product development and user experience — with an Android app on the roadmap. “Our aim is to get the business into shape for series A, which will be sometime next year,” he adds. While Echo is free for patients and doctors to use (patients just pay the standard NHS prescription fee of £8.40 per item, unless they are entitled to free prescriptions), the business model involves Echo taking a commission cut from its pharmacy partners, based on the additional business the app sends their way. (He declines to specify what the commission, saying only: “Echo takes a commission based on the gross profit available to our pharmacy partners.”) Both founders have their own need for repeat prescriptions — leading them to the idea for the app. Bourke also previously worked at Lloyds Pharmacy. “The market is huge,” he adds. “There are over 1.2 billion prescription items issued in the UK each year, with the NHS spending over £15.5 billion on medication. “Half the adult population now takes a repeat prescription and this is set to increase. Top-line user growth is important, but our real focus is on driving repeat rates, maintaining Echo’s net promotor score (currently 89) and ensuring that we can deliver a user experience 10x better than the rest. We will only scale once we are confident we can do so without jeopardizing quality.” While Echo remains fully focused on the UK market for now, the founders certainly see potential to scale their app internationally. “I previously launched LloydsPharmacy’s online doctor business in Ireland and Australia, so we definitely see an opportunity to expand our services and geographic reach,” says Bourke. “European healthcare systems are desperately in need of fresh ideas, competition and disruption. However, right now we are laser focused on the NHS and UK for now, and will continue to be so until we nail product-market-fit.” “Competition is hotting up in the US – PillPack is an obvious reference point. An important point of differentiation is that Echo is not a pharmacy — our goal is to improve medication adherence through technology. It is also free, and works with existing NHS infrastructure so there is no set-up for the user or their GP.  In the future we will likely work with other clinical services in a similar way to our pharmacy partners today, but todays all focus is on adherence and user experience,” he adds.

Loading Lloyds Pharmacy collaborators
Loading Lloyds Pharmacy collaborators